Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lisa Takagi

Managing Editor

Tokyo, Japan

Lisa provides editorial coverage of all aspects of Japan’s prescription drug market for Scrip and Pink Sheet, including company, market, pricing and regulatory developments, as well as publishing podcast content regularly in the local Japanese language.

Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she covered the IT sector for ITmedia Enterprise in Japan. Lisa is bilingual in Japanese and English. She speaks basic French and Mandarin with keen interests in learning new languages. She holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada.

Latest From Lisa Takagi

US Fast Track Boosts Sumitomo's Oncology Pivot

Sumitomo’s novel AML candidate has shown early clinical promise and been granted US Fast Track status for a form of AML, which looks set to aid the Japanese firm's strategic shift to oncology following recent CNS setbacks. 

Research & Development Cancer

Japan Phase III Wins, Asian Alliances Buoy Kissei's Linzagolix

While its European licensee is preparing for an imminent launch, Kissei has also been expanding its partnerships in Asia for female health product linzagolix. A new alliance is also being sought in the US to assist with a new trial and NDA refiling there.

Women's Health Research & Development

Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents

Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.

Deal Watch Business Strategies

Chiesi Takes Long View To Build Japan Rare Disease Presence

After expanding its local portfolio through acquisitions and partnerships, Chiesi is now aiming to build its presence in Japan's rare disease sector over the long term, helped by development of global products and possible new alliances. 

Japan Rare Diseases

Japan Makes Renewed Policy Efforts To Fill 'Drug Gap'

Japan has announced several new measures to tackle the lack of rare disease and other therapeutics in the domestic market, with the country's main industry association also issuing the first common national informed consent form in a bid to lighten the “huge workload” on trial site staff.

Japan Drug Review

PRISM BioLab Completes Successful Tokyo IPO On Back Of Multiple Partnerships

The Japanese drug discovery bioventure builds on multiple alliances and an in-house platform to get away a successful IPO in Tokyo, which it will use to fund further pipeline and technology development.

Japan Commercial
See All